MEPAN syndrome
| MEPAN syndrome | |
|---|---|
| Other names | Mitochondrial enoyl CoA reductase protein-associated neurodegeneration syndrome; MECR-related neurologic disorder; Dystonia, childhood-onset, with optic atrophy and basal ganglia abnormalities (DYTOABG); Autosomal recessive childhood-onset dystonia, DYT29 type; Childhood-onset generalized dystonia-optic atrophy syndrome; DYT29; Dystonia 29 |
| Ribbon diagram of mitochondrial trans-2-enoyl-CoA reductase (MECR) | |
| Specialty | Medical genetics |
| Usual onset | Childhood, Infancy |
| Causes | Pathogenic biallelic variants in the MECR gene |
| Diagnostic method | Molecular genetic testing |
| Frequency | <1:1,000,000 |
Mitochondrial enoyl reductase protein-associated neurodegeneration (MePAN, MEPAN), also known as MEPAN syndrome, is a rare genetic mitochondrial metabolic disorder. It typically presents in early childhood with dystonia, optic atrophy, and basal ganglia signal abnormalities, although an LHON-like optic neuropathy presentation has also been reported. The disorder is caused by pathogenic variants in the MECR gene, which encodes mitochondrial trans-2-enoyl-CoA reductase (MECR), the enzyme responsible for the last step of mitochondrial fatty acid synthesis (mtFAS). MEPAN was first described by Heimer et al. in 2016.